Are self-care interventions effective for the management of skin neglected tropical diseases in Anambra State, Nigeria?

Effectiveness of self-care interventions for integrated morbidity management of skin neglected tropical diseases in Anambra State, Nigeria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN20317241

Enrollment

Registered

2021-08-27

Start date

2017-12-01

Completion date

Unknown

Last updated

2021-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin neglected tropical diseases: Leprosy, Buruli Ulcer (BU), or Lymphatic Filariasis (LF) and non-neglected tropical diseases skin lesions (such as diabetic ulcers, sickle cell disease and trauma) Skin and Connective Tissue Diseases

Interventions

In the study setting, the cadre of healthcare workers involved in the project are community health extension workers and community health officers. The self-care intervention for integrated morbidity

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with LF, BU or leprosy 2. Completed specific treatment for their condition but still had morbidities requiring additional care

Exclusion criteria

Exclusion criteria: Participants who had no impairment due to neglected tropical diseases or related conditions with similar impairment

Design outcomes

Primary

Measure	Time frame
1. Self-reported economic costs of managing the impairment or lesion before (December 2017) and after (May/June 2018) the intervention period assessed with a costing tool 2. Disability status due to the impairment or lesion before (December 2017) and after (May/June 2018) the intervention period assessed using the World Health Organization Disability Scale-2 (WHODAS-2.0) 3. Quality of life due to the impairment or lesion before (December 2017) and after (May/June 2018) the intervention period assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) tool	—

Measure

Time frame

1. Self-reported economic costs of managing the impairment or lesion before (December 2017) and after (May/June 2018) the intervention period assessed with a costing tool 2. Disability status due to the impairment or lesion before (December 2017) and after (May/June 2018) the intervention period assessed using the World Health Organization Disability Scale-2 (WHODAS-2.0) 3. Quality of life due to the impairment or lesion before (December 2017) and after (May/June 2018) the intervention period assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) tool

—

Secondary

Measure	Time frame
1. Self-reported economic costs of managing the impairment or lesion assessed with a costing tool by patients who provided baseline data but did not complete follow-up compared to those who completed follow-up. 2. Disability status due to the impairment or lesion assessed using the World Health Organization Disability Scale-2 (WHODAS-2.0) by patients who provided baseline data but did not complete follow-up compared to those who completed follow-up. 3. Quality of life due to the impairment or lesion assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) tool by patients who provided baseline data but did not complete follow-up compared to those who completed follow-up.	—

Measure

Time frame

1. Self-reported economic costs of managing the impairment or lesion assessed with a costing tool by patients who provided baseline data but did not complete follow-up compared to those who completed follow-up. 2. Disability status due to the impairment or lesion assessed using the World Health Organization Disability Scale-2 (WHODAS-2.0) by patients who provided baseline data but did not complete follow-up compared to those who completed follow-up. 3. Quality of life due to the impairment or lesion assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) tool by patients who provided baseline data but did not complete follow-up compared to those who completed follow-up.

—

Countries

Nigeria

Contacts

Public ContactChinwe Eze

chinwe.eze@dahw.org+234 9032716409

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 21, 2026